Probi Digestis®

Overview

The human digestive system is an ecosystem in which beneficial and harmful bacteria are in balance. Disruption of this balance can lead to digestive discomfort.

Approximately half of the world’s population regularly experiences functional gastrointestinal problems, and 5–35% are affected by irritable bowel syndrome (IBS), with symptoms such as bloating, constipation and abdominal pain.

Probi Digestis® contains Lactiplantibacillus plantarum 299v (LP299V®), an extensively researched strain clinically shown to support gastrointestinal health and restore balance. LP299V® is one of the most well-documented probiotic bacteria in the world.

Applications

Probi Digestis® is suitable for capsules, tablets and stick packs, as well as for functional foods such as beverages and powder products.

Key features

It has been clinically shown to support gastrointestinal health.

It has been reported to reduce certain gastrointestinal symptoms during antibiotic treatment.

It has been reported to reduce the incidence of Clostridium difficile infection in a nephrology and transplantation ward.

In IBS treatment, success has been observed to increase with the length of treatment.

Related publications:

Goodoory V.C., Ford A.C. “Antibiotics and Probiotics for Irritable Bowel Syndrome.” Drugs 2023;83(8):687-699.

Lönnermark E. et al. “Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics.” Journal of Clinical Gastroenterology 2010;44:106-112.

Dudzicz S. et al. “Lactobacillus plantarum 299v Reduces the Incidence of Clostridium difficile Infection in Nephrology and Transplantation Ward.” Nutrients 2018;10(11):1574.

Krammer H., Storr M., Madisch A., Riffel J. “Treatment of IBS with Lactobacillus plantarum 299v.” Z Gastroenterol 2021;59(02):125-134.